nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.03.2015 | Clinical

Immunotherapy of melanoma: Present options and future promises

verfasst von: Anand Rotte, Madhuri Bhandaru, Youwen Zhou, Kevin J. McElwee

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Metastatic melanoma is notorious for its immune evasion and resistance to conventional chemotherapy. The recent success of ipilimumab, a human monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), in increasing the median survival time and stabilizing the disease progression renewed, hopes in treatment for melanoma. Currently, ipilimumab and high-dose interleukin-2 (IL-2; Aldesleukin) are approved as monotherapies for the treatment of patients with unresectable advanced melanoma, and pegylated interferon-α2b (p-IFN-α2b) is approved as an adjuvant for the treatment of patients with surgically resected high-risk melanoma. The present review describes the currently approved immune-modulators and the promising immune-based interventions that are currently in clinical trials. We present the four commonly used strategies to boost immune responses against the tumors; monoclonal antibodies, cytokines, cancer vaccines, and adoptive T cell transfer. The corresponding lists of ongoing clinical trials include details of the trial phase, target patients, intervention details, status of the study, and expected date of completion. Further, our review discusses the challenges faced by immunotherapy and the various strategies adopted to overcome them.

Miller, A. J., & Mihm, M. C., Jr. (2006). Melanoma. New England Journal of Medicine, 355(1), 51–65. doi:10.1056/NEJMra052166.CrossRefPubMed

Siegel, R., Naishadham, D., & Jemal, A. (2013). Cancer statistics, 2013. CA: A Cancer Journal for Clinicians, 63(1), 11–30. doi:10.3322/caac.21166.

Cheng, Y., Zhang, G., & Li, G. (2013). Targeting MAPK pathway in melanoma therapy. Cancer and Metastasis Reviews, 32(3–4), 567–584. doi:10.1007/s10555-013-9433-9.CrossRefPubMed

Saranga-Perry, V., Ambe, C., Zager, J. S., & Kudchadkar, R. R. (2014). Recent developments in the medical and surgical treatment of melanoma. CA: A Cancer Journal for Clinicians, 64(3), 171–185. doi:10.3322/caac.21224.

Finn, L., Markovic, S. N., & Joseph, R. W. (2012). Therapy for metastatic melanoma: the past, present, and future. BMC Medicine, 10, 23. doi:10.1186/1741-7015-10-23.CrossRefPubMedPubMedCentral

Hodi, F. S., Oble, D. A., Drappatz, J., Velazquez, E. F., Ramaiya, N., Ramakrishna, N., et al. (2008). CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nature Clinical Practice Oncology, 5(9), 557–561. doi:10.1038/ncponc1183.CrossRefPubMed

Hodi, F. S., O’Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711–723. doi:10.1056/NEJMoa1003466.CrossRefPubMedPubMedCentral

Robert, C., Thomas, L., Bondarenko, I., O’Day, S., Weber, J., Garbe, C., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine, 364(26), 2517–2526. doi:10.1056/NEJMoa1104621.CrossRefPubMed

Postow, M. A., Luke, J. J., Bluth, M. J., Ramaiya, N., Panageas, K. S., Lawrence, D. P., et al. (2013). Ipilimumab for patients with advanced mucosal melanoma. The Oncologist, 18(6), 726–732. doi:10.1634/theoncologist. 2012-0464.CrossRefPubMedPubMedCentral

10.

Rosenberg, S. A. (2014). IL-2: the first effective immunotherapy for human cancer. Journal of Immunology, 192(12), 5451–5458. doi:10.4049/jimmunol.1490019.CrossRef

11.

Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., et al. (1999). High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. Journal of Clinical Oncology, 17(7), 2105–2116.PubMed

12.

Kaufman, H. L., Kirkwood, J. M., Hodi, F. S., Agarwala, S., Amatruda, T., Bines, S. D., et al. (2013). The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nature Reviews. Clinical Oncology, 10(10), 588–598. doi:10.1038/nrclinonc.2013.153.CrossRefPubMed

13.

Okuyama, S., Gonzalez, R., & Lewis, K. D. (2010). Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review. Core Evidence, 5, 39–48.PubMedPubMedCentral

14.

Kirkwood, J. M., & Ernstoff, M. S. (1984). Interferons in the treatment of human cancer. Journal of Clinical Oncology, 2(4), 336–352.PubMed

15.

Tarhini, A. A., Gogas, H., & Kirkwood, J. M. (2012). IFN-alpha in the treatment of melanoma. Journal of Immunology, 189(8), 3789–3793. doi:10.4049/jimmunol.1290060.CrossRef

16.

Herndon, T. M., Demko, S. G., Jiang, X., He, K., Gootenberg, J. E., Cohen, M. H., et al. (2012). U.S. food and drug administration approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma. The Oncologist, 17(10), 1323–1328. doi:10.1634/theoncologist. 2012-0123.CrossRefPubMedPubMedCentral

17.

Weber, J. (2007). Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. The Oncologist, 12(7), 864–872. doi:10.1634/theoncologist.12-7-864.CrossRefPubMed

18.

Dariavach, P., Mattei, M. G., Golstein, P., & Lefranc, M. P. (1988). Human Ig superfamily CTLA-4 gene: Chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. European Journal of Immunology, 18(12), 1901–1905. doi:10.1002/eji.1830181206.CrossRefPubMed

19.

Karandikar, N. J., Vanderlugt, C. L., Walunas, T. L., Miller, S. D., & Bluestone, J. A. (1996). CTLA-4: a negative regulator of autoimmune disease. Journal of Experimental Medicine, 184(2), 783–788.CrossRefPubMed

20.

Walunas, T. L., Bakker, C. Y., & Bluestone, J. A. (1996). CTLA-4 ligation blocks CD28-dependent T cell activation. Journal of Experimental Medicine, 183(6), 2541–2550.CrossRefPubMed

21.

Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., et al. (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America, 100(14), 8372–8377. doi:10.1073/pnas.1533209100.CrossRefPubMedPubMedCentral

22.

Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. New England Journal of Medicine, 369(2), 122–133. doi:10.1056/NEJMoa1302369.CrossRefPubMed

23.

Kyi, C., & Postow, M. A. (2014). Checkpoint blocking antibodies in cancer immunotherapy. FEBS Letters, 588(2), 368–376. doi:10.1016/j.febslet.2013.10.015.CrossRefPubMed

24.

McDermott, D. F., & Atkins, M. B. (2013). PD-1 as a potential target in cancer therapy. Cancer Medicine, 2(5), 662–673. doi:10.1002/cam4.106.PubMedPubMedCentral

25.

Merelli, B., Massi, D., Cattaneo, L., & Mandala, M. (2014). Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Critical Reviews in Oncology/Hematology, 89(1), 140–165. doi:10.1016/j.critrevonc.2013.08.002.CrossRefPubMed

26.

Zou, W., & Chen, L. (2008). Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews Immunology, 8(6), 467–477. doi:10.1038/nri2326.CrossRefPubMed

27.

Inman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I., et al. (2007). PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: Associations with localized stage progression. Cancer, 109(8), 1499–1505. doi:10.1002/cncr.22588.CrossRefPubMed

28.

Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., et al. (2004). Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 101(49), 17174–17179. doi:10.1073/pnas.0406351101.CrossRefPubMedPubMedCentral

29.

Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., et al. (2007). Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clinical Cancer Research, 13(7), 2151–2157. doi:10.1158/1078-0432.CCR-06-2746.CrossRefPubMed

30.

Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., et al. (2007). Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 104(9), 3360–3365. doi:10.1073/pnas.0611533104.CrossRefPubMedPubMedCentral

31.

Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., et al. (2003). Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Research, 63(21), 7462–7467.PubMed

32.

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., et al. (2014). Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Journal of Clinical Oncology, 32(10), 1020–1030. doi:10.1200/JCO.2013.53.0105.CrossRefPubMedPubMedCentral

33.

Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., et al. (2014). Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, 384(9948), 1109–1117. doi:10.1016/S0140-6736(14)60958-2.CrossRefPubMed

34.

Thomas, L. J., He, L. Z., Marsh, H., & Keler, T. (2014). Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity. Oncoimmunology, 3(1), e27255. doi:10.4161/onci.27255.CrossRefPubMedPubMedCentral

35.

Denoeud, J., & Moser, M. (2011). Role of CD27/CD70 pathway of activation in immunity and tolerance. Journal of Leukocyte Biology, 89(2), 195–203. doi:10.1189/jlb.0610351.CrossRefPubMed

36.

Schaer, D. A., Hirschhorn-Cymerman, D., & Wolchok, J. D. (2014). Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. Journal of Immunotherapy Cancer, 2, 7. doi:10.1186/2051-1426-2-7.CrossRef

37.

Vitale, L. A., He, L. Z., Thomas, L. J., Widger, J., Weidlick, J., Crocker, A., et al. (2012). Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clinical Cancer Research, 18(14), 3812–3821. doi:10.1158/1078-0432.CCR-11-3308.CrossRefPubMed

38.

Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005). The B7 family revisited. Annual Review of Immunology, 23, 515–548. doi:10.1146/annurev.immunol.23.021704.115611.CrossRefPubMed

39.

Leitner, J., Klauser, C., Pickl, W. F., Stockl, J., Majdic, O., Bardet, A. F., et al. (2009). B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. European Journal of Immunology, 39(7), 1754–1764. doi:10.1002/eji.200839028.CrossRefPubMedPubMedCentral

40.

Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., et al. (2001). B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nature Immunology, 2(3), 269–274. doi:10.1038/85339.CrossRefPubMed

41.

Loo, D., Alderson, R. F., Chen, F. Z., Huang, L., Zhang, W., Gorlatov, S., et al. (2012). Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clinical Cancer Research, 18(14), 3834–3845. doi:10.1158/1078-0432.CCR-12-0715.CrossRefPubMed

42.

Daleke, D. L. (2003). Regulation of transbilayer plasma membrane phospholipid asymmetry. Journal of Lipid Research, 44(2), 233–242. doi:10.1194/jlr. R200019-JLR200.CrossRefPubMed

43.

Lang, F., Gulbins, E., Lang, P. A., Zappulla, D., & Foller, M. (2010). Ceramide in suicidal death of erythrocytes. Cellular Physiology and Biochemistry, 26(1), 21–28. doi:10.1159/000315102.CrossRefPubMed

44.

Lang, F., & Qadri, S. M. (2012). Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purification, 33(1–3), 125–130. doi:10.1159/000334163.CrossRefPubMed

45.

Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998). Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. Journal of Clinical Investigation, 101(4), 890–898. doi:10.1172/JCI1112.CrossRefPubMedPubMedCentral

46.

Gerber, D. E., Stopeck, A. T., Wong, L., Rosen, L. S., Thorpe, P. E., Shan, J. S., et al. (2011). Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clinical Cancer Research, 17(21), 6888–6896. doi:10.1158/1078-0432.CCR-11-1074.CrossRefPubMed

47.

Kaufman, H. L., Ruby, C. E., Hughes, T., & Slingluff, C. L., Jr. (2014). Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. Journal of Immunotherapy Cancer, 2, 11. doi:10.1186/2051-1426-2-11.CrossRef

48.

Shi, Y., Liu, C. H., Roberts, A. I., Das, J., Xu, G., Ren, G., et al. (2006). Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don’t know. Cell Research, 16(2), 126–133. doi:10.1038/sj.cr.7310017.CrossRefPubMed

49.

Matzinger, P. (2002). The danger model: a renewed sense of self. Science, 296(5566), 301–305. doi:10.1126/science.1071059.CrossRefPubMed

50.

Traversari, C., van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., Van Pel, A., et al. (1992). A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. Journal of Experimental Medicine, 176(5), 1453–1457.CrossRefPubMed

51.

van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., et al. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254(5038), 1643–1647.CrossRefPubMed

52.

Aranda, F., Vacchelli, E., Eggermont, A., Galon, J., Sautes-Fridman, C., Tartour, E., et al. (2013). Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology, 2(12), e26621. doi:10.4161/onci.26621.CrossRefPubMedPubMedCentral

53.

Murakami, T., & Sunada, Y. (2011). Plasmid DNA gene therapy by electroporation: Principles and recent advances. Current Gene Therapy, 11(6), 447–456.CrossRefPubMed

54.

USDA licenses DNA vaccine for treatment of melanoma in dogs (2010). J Am Vet Med Assoc, 236(5), 495, doi: 10.2460/javma.236.5.488.

55.

Bergman, P. J., Camps-Palau, M. A., McKnight, J. A., Leibman, N. F., Craft, D. M., Leung, C., et al. (2006). Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine, 24(21), 4582–4585. doi:10.1016/j.vaccine.2005.08.027.CrossRefPubMed

56.

Bergman, P. J., McKnight, J., Novosad, A., Charney, S., Farrelly, J., Craft, D., et al. (2003). Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clinical Cancer Research, 9(4), 1284–1290.PubMed

57.

Palucka, K., & Banchereau, J. (2012). Cancer immunotherapy via dendritic cells. Nature Reviews Cancer, 12(4), 265–277. doi:10.1038/nrc3258.CrossRefPubMedPubMedCentral

58.

El Marsafy, S., Bagot, M., Bensussan, A., & Mauviel, A. (2009). Dendritic cells in the skin—Potential use for melanoma treatment. Pigment Cell & Melanoma Research, 22(1), 30–41. doi:10.1111/j.1755-148X.2008.00532.x.CrossRef

59.

Radford, K. J., Tullett, K. M., & Lahoud, M. H. (2014). Dendritic cells and cancer immunotherapy. Current Opinion in Immunology, 27, 26–32. doi:10.1016/j.coi.2014.01.005.CrossRefPubMed

60.

Kobayashi, M., Suzuki, K., Yashi, M., Yuzawa, M., Takayashiki, N., & Morita, T. (2007). Tumor infiltrating dendritic cells predict treatment response to immunotherapy in patients with metastatic renal cell carcinoma. Anticancer Research, 27(2), 1137–1141.PubMed

61.

Simonetti, O., Goteri, G., Lucarini, G., Rubini, C., Stramazzotti, D., Lo Muzio, L., et al. (2007). In melanoma changes of immature and mature dendritic cell expression correlate with tumor thickness: an immunohistochemical study. International Journal of Immunopathology and Pharmacology, 20(2), 325–333.PubMed

62.

Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F., & Berneman, Z. N. (2014). Clinical use of dendritic cells for cancer therapy. Lancet Oncology, 15(7), e257–e267. doi:10.1016/S1470-2045(13)70585-0.CrossRefPubMed

63.

Weber, J., Atkins, M., Hwu, P., Radvanyi, L., Sznol, M., & Yee, C. (2011). White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clinical Cancer Research, 17(7), 1664–1673. doi:10.1158/1078-0432.CCR-10-2272.CrossRefPubMed

64.

Park, T. S., Rosenberg, S. A., & Morgan, R. A. (2011). Treating cancer with genetically engineered T cells. Trends in Biotechnology, 29(11), 550–557. doi:10.1016/j.tibtech.2011.04.009.CrossRefPubMedPubMedCentral

65.

Lee, S., & Margolin, K. (2012). Tumor-infiltrating lymphocytes in melanoma. Current Oncology Reports, 14(5), 468–474. doi:10.1007/s11912-012-0257-5.CrossRefPubMedPubMedCentral

66.

Urba, W. J. (2014). At the bench: Adoptive cell therapy for melanoma. Journal of Leukocyte Biology, 95(6), 867–874. doi:10.1189/jlb.0513301.CrossRefPubMed

67.

Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C. N., Sloss, C. M., et al. (2010). Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Research, 70(13), 5213–5219. doi:10.1158/0008-5472.CAN-10-0118.CrossRefPubMed

68.

Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., et al. (2012). Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clinical Cancer Research, 18(5), 1386–1394. doi:10.1158/1078-0432.CCR-11-2479.CrossRefPubMed

69.

Koya, R. C., Mok, S., Otte, N., Blacketor, K. J., Comin-Anduix, B., Tumeh, P. C., et al. (2012). BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Research, 72(16), 3928–3937. doi:10.1158/0008-5472.CAN-11-2837.CrossRefPubMedPubMedCentral

70.

Eggermont, A. M., Suciu, S., Testori, A., Santinami, M., Kruit, W. H., Marsden, J., et al. (2012). Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. Journal of Clinical Oncology, 30(31), 3810–3818. doi:10.1200/JCO.2011.41.3799.CrossRefPubMed

71.

Kelderman, S., Schumacher, T. N., & Haanen, J. B. (2014). Acquired and intrinsic resistance in cancer immunotherapy. Molecular Oncology. doi:10.1016/j.molonc.2014.07.011.PubMed

72.

Baitsch, L., Fuertes-Marraco, S. A., Legat, A., Meyer, C., & Speiser, D. E. (2012). The three main stumbling blocks for anticancer T cells. Trends in Immunology, 33(7), 364–372. doi:10.1016/j.it.2012.02.006.CrossRefPubMed

73.

Besedovsky, L., Lange, T., & Born, J. (2012). Sleep and immune function. Pflügers Archiv, 463(1), 121–137. doi:10.1007/s00424-011-1044-0.CrossRefPubMedPubMedCentral

74.

Segerstrom, S. C., & Miller, G. E. (2004). Psychological stress and the human immune system: a meta-analytic study of 30 years of inquiry. Psychological Bulletin, 130(4), 601–630. doi:10.1037/0033-2909.130.4.601.CrossRefPubMedPubMedCentral

75.

Kasparian, N. A. (2013). Psychological care for people with melanoma: what, when, why and how? Seminars in Oncology Nursing, 29(3), 214–222. doi:10.1016/j.soncn.2013.06.007.CrossRefPubMed

76.

Kasparian, N. A. (2013). Psychological stress and melanoma: are we meeting our patients’ psychological needs? Clinics in Dermatology, 31(1), 41–46. doi:10.1016/j.clindermatol.2011.11.005.CrossRefPubMed

77.

Fellner, C. (2012). Ipilimumab (yervoy) prolongs survival in advanced melanoma: Serious side effects and a hefty price tag may limit its use. P T, 37(9), 503–530.PubMedPubMedCentral

78.

Jonsson, B., & Wilking, N. (2012). Cancer vaccines and immunotherapeutics: Challenges for pricing, reimbursement and market access. Human Vaccin Immunotherapy, 8(9), 1360–1363. doi:10.4161/hv.21921.CrossRef

79.

Ma, C., & Armstrong, A. W. (2014). Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. The Journal of Dermatological Treatment, 25(5), 401–408. doi:10.3109/09546634.2013.813897.CrossRefPubMed

80.

Amos, S. M., Duong, C. P., Westwood, J. A., Ritchie, D. S., Junghans, R. P., Darcy, P. K., et al. (2011). Autoimmunity associated with immunotherapy of cancer. Blood, 118(3), 499–509. doi:10.1182/blood-2011-01-325266.CrossRefPubMed

81.

Lacouture, M. E., Wolchok, J. D., Yosipovitch, G., Kahler, K. C., Busam, K. J., & Hauschild, A. (2014). Ipilimumab in patients with cancer and the management of dermatologic adverse events. Journal of the American Academy of Dermatology, 71(1), 161–169. doi:10.1016/j.jaad.2014.02.035.CrossRefPubMed

82.

Minkis, K., Garden, B. C., Wu, S., Pulitzer, M. P., & Lacouture, M. E. (2013). The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. Journal of the American Academy of Dermatology, 69(3), e121–e128. doi:10.1016/j.jaad.2012.12.963.CrossRefPubMed

83.

Bouwhuis, M. G., Ten Hagen, T. L., Suciu, S., & Eggermont, A. M. (2011). Autoimmunity and treatment outcome in melanoma. Current Opinion in Oncology, 23(2), 170–176. doi:10.1097/CCO.0b013e328341edff.CrossRefPubMed

84.

Hinds, A. M., Ahmad, D. S., Muenster, J. E., Berg, Z. M., Lopez, K. T., Holly, J. S., et al. (2014). Ipilimumab-induced colitis: a rare but serious side effect. Endoscopy, 46(Suppl 1 UCTN), E308–E309. doi:10.1055/s-0034-1377209.PubMed

Titel: Immunotherapy of melanoma: Present options and future promises
verfasst von: Anand Rotte
Madhuri Bhandaru
Youwen Zhou
Kevin J. McElwee
Publikationsdatum: 01.03.2015
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2015
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-014-9542-0

Springer Medizin

Immunotherapy of melanoma: Present options and future promises

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Proteomics of ovarian cancer: functional insights and clinical applications

The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal

Erratum to: Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy

Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?

Biographies

Exploring alternative ovarian cancer biomarkers using innovative nanotechnology strategies

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie